MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5435/jaaos-d-25-00392

Медицинская библиотека · The Journal of the American Academy of Orthopaedic Surgeons · 2025

Influence of Chimeric Antigen Receptor T-Cell Therapy on Fracture Risk of Patients With Multiple Myeloma.

Huynh Thien Huong N, Clampitt Bryan A, Chose Chloe M, Nester Matthew D, Joyce David M, Binitie Odion T, Freeman Ciara L, Lazarides Alexander L

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Patients with relapsed or refractory multiple myeloma (MM) often have a high burden of skeletal disease and may be at risk for pathologic fracture. These patients may be eligible for chimeric antigen receptor T-cell (CAR-T) therapy. However, little is known about the effect of CAR-T therapy on a patient's fracture risk. The purpose of this study is to evaluate this effect.

METHODS

A consecutive cohort of MM patients undergoing treatment with CAR-T therapy were reviewed retrospectively. Patients were required to have a PET-CT before CAR-T infusion and at least one PET-CT surveillance imaging 90 days following treatment. The minimum follow-up for surviving patients was set at 3 months. The primary outcome measure was fracture risk as characterized by a modified Mirels criteria. The secondary outcome measure was change in lesion avidity, measured as standardized uptake value units, on PET-CT. Survival was investigated by Kaplan-Meier method.

RESULTS

We identified 139 patients who underwent CAR-T for MM. Overall, 71 patients (51.4%) had a discrete long bone lesion, and 37 patients (27.8%) were characterized as being "at risk" for fracture before infusion. After CAR-T, three patients (2.5%) were identified as being at risk ( P = 0.004). The mean PET-CT standardized uptake value between at risk patients and those at low risk was markedly different before infusion (9.18 vs. 6.75, P = 0.03). For these same patients, no difference was identified after CAR-T therapy (5.75 vs. 4.67, P = 0.26). Three fractures occurred in the posttransfusion period; 33 patients (23.7%) died of disease after CAR-T therapy at a mean of 6.6 months.

CONCLUSION

Following CAR-T infusion, a notable reduction was observed in fracture risk, suggesting that CAR-T could be valuable not only in managing MM but also in managing the risk of pathologic fracture that comes with this malignancy.

Для цитирования: Huynh Thien Huong N, Clampitt Bryan A, Chose Chloe M, Nester Matthew D, Joyce David M, Binitie Odion T, Freeman Ciara L, Lazarides Alexander L. Influence of Chimeric Antigen Receptor T-Cell Therapy on Fracture Risk of Patients With Multiple Myeloma.. The Journal of the American Academy of Orthopaedic Surgeons. 2025. DOI: 10.5435/jaaos-d-25-00392.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.